Novo Nordisk and Eli Lilly are battling it out in the weight-loss drug market with price cuts on Wegovy and Zepbound. Also, investment firms adjust their positions in KKR and Blue Owl. Read more...

This week in health: a study on postpartum depression and brain changes, the risks of overhydration, and the potential pitfalls of weight-loss drugs like Ozempic. Plus, a ruling on cosmetic surgery. Read more...

Wes Streeting faces NHS challenges with a three-point plan and calls for retailer accountability after a teen bought weight-loss drugs. Starmer's peace plan also emerges. Read more...